Pharma Focus Asia

ASLAN Pharmaceuticals Enters into Licencing Agreement with Zenyaku Kogyo

Friday, June 23, 2023

ASLAN Pharmaceuticals and Zenyaku Kogyo have recently entered into a strategic licensing agreement.

Under this agreement, ASLAN Pharmaceuticals has granted Zenyaku Kogyo exclusive rights to develop and commercialize eblasakimab in Japan.

As part of the strategic licensing agreement between ASLAN Pharmaceuticals and Zenyaku Kogyo, ASLAN is set to receive up to $15 million in upfront and near-term payments. In addition to this initial payment, ASLAN may also be eligible to receive milestone payments based on specific developmental and commercial achievements related to eblasakimab in Japan.

The collaboration between ASLAN Pharmaceuticals and Zenyaku Kogyo represents a significant expansion of dermatology portfolio, particularly in the treatment of moderate-to-severe atopic dermatitis (AD). Based on the positive data to date, Eblasakimab, with its unique mechanism of action, offers the potential for a safe, effective, and convenient therapeutic option for patients with AD.

Eblasakimab is a potential first-in-class monoclonal antibody that targets the IL-13 receptor subunit of the Type 2 receptor.

magazine-slider-imageCytiva - Supor Prime filtersMFA + MMA 2024CPHI China || PMEC China 2024Asia Healthcare Week 2024CPHI Korea 2024CHEMICAL INDONESIA 2024World Orphan Drug Congress Europe 2024INALAB 2024Thermo Fisher - Drug Discovery and the impact of mAbsAdvanced Therapies USA 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference3rd World ADC Asia 2024LogiPharma Asia 2024